Sensorion (FRA:RFM) Marketable Securities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RFM Sensorion SA FRA:RFM
16 GF Score
Price €0.25
! 1 Warning Sign
View Full Analysis

What is Sensorion Marketable Securities?

Sensorion FRA:RFM +8.78% 16 Marketable Securities is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:RFM with a GF Score™ of 16/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sensorion's Marketable Securities for the quarter that ended in Dec. 2025 was €0.00 Mil.

Sensorion's annual Marketable Securities increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€10.21 Mil) but then declined from Dec. 2024 (€10.21 Mil) to Dec. 2025 (€0.00 Mil).

Sensorion  (FRA:RFM) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sensorion Marketable Securities Related Terms

Sensorion Marketable Securities Historical Data

* Premium members only.

The historical data trend for Sensorion's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensorion Marketable Securities Chart

Sensorion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 10.21 0.00

Sensorion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 10.21 10.42 0.00
FRA:RFM
16GF Score
Sensorion SA FRA:RFM
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sensorion Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Sensorion (FRA:RFM) has a Marketable Securities of €0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sensorion and its competitors.
Is Sensorion's Marketable Securities too high?
Sensorion's current Marketable Securities is €0.00 Mil. Overall, Sensorion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Sensorion's Marketable Securities compare to VRTX and REGN?
Sensorion's Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sensorion and its competitors. Sensorion's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Sensorion (FRA:RFM) has a current Marketable Securities of €0.00 Mil. The current Marketable Securities is €0.00 Mil. Sensorion's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sensorion (FRA:RFM), the current Marketable Securities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sensorion Business Description

Other Exchanges ALSEN:FranceRFM:Germany
Address 375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
16GF Score

Get the complete analysis for FRA:RFM

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price